Emergence, virology, immune response after SARS‐CoV‐2 infection, and role of immunopathology behind vaccination

Authors

  • Priyadharshini R Department of Pathology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India
  • Brundha M.P. Department of Pathology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India
  • Sinduja Palati Department of Pathology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India

Keywords:

Immune response, immunopathology, SARS-CoV-2, virology

Abstract

In mid-January 2020, the WHO received information from the International Commission of Health about
an outbreak of disease in the capital of Hubei province, Wuhan, in Central China. There was no evidence
of human transmission or infection among health-care workers at that stage. Initially, the cases identified
visiting the Wuhan live and seafood market prompted a suspicion that might be the source of the pandemic.
Stumbling of more than 200 vaccines started with preclinical progress, but only approximately 40 vaccines
entered clinical trials where some were not approved for human trials. This review addresses the genome
sequence, immunopathology induced by virus, and vaccine.

Downloads

Published

2022-08-17

How to Cite

R, P., M.P., B., & Sinduja Palati. (2022). Emergence, virology, immune response after SARS‐CoV‐2 infection, and role of immunopathology behind vaccination. International Journal of Clinicopathological Correlation, 5(2), 45–48. Retrieved from https://editorialmanager.in/index.php/ijcpc/article/view/352

Issue

Vol. 5 No. 2 (2021): Jul-Dec

Section

Review

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.